• Critique of hydroxychloroquine studies to date

    There has been a lot of controversy about hydroxychloroquine (HCQ) as a therapeutic intervention for COVID-19. Given the recently available studies suggesting little or no benefit of HCQ and potential harm we have received questions about; Should we continue to include HCQ? Or should we be using this dose of HCQ?

  • BHP Foundation commits $3M to prevention and treatment of COVID-19

    The BHP Foundation has generously committed $1 million for the AustralaSian COVID-19 Trial (ASCOT), a clinical trial aimed at testing the effectiveness and safety of potential drugs in patients hospitalised with COVID-19.
  • Keeping up with COVID

    AustralaSian COVID-19 Trial (ASCOT) has launched with a focus on evaluating two medications with early suggestions of potential benefit in hospitalised patients with SARS-CoV-2; hydroxychloroquine and lopinavir/ritonavir. Both are repurposed medications, meaning that they have been used for other conditions before.
  • New COVID-19 treatments explainer in ABC News

    An explainer 'Hydroxychloroquine, antibody therapy and antivirals: The coronavirus treatments being investigated and how long they might take' writ...
  • The COVID-19 treatment trials that ‘learn as they go’

    Innovative COVID-19 treatment trials enable us to quickly hone in on the most promising treatments, saving time and potentially saving lives.